8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Feb 12, 2026·SEC
Material company update
Jan 23, 2026·SEC
Soligenix, Inc.(SNGX)Earnings, Financials & Key Ratios
SNGX•NASDAQ
Price updated Jun 19, 2026
AboutSoligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including SGX203 for pediatric Crohn's disease; and SGX302 that is in Phase I/II clinical trial for the treatment of mild-to-moderate psoriasis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase Ia and Ib clinical trials; SGX943, a therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; and CiVax, a vaccine candidate in pre-clinical development for the prevention of COVID-19. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.Show more
- Revenue$0
- EBITDA-$12M-25.5%
- Net Income-$11M-34.0%
- EPS (Diluted)-2.14+57.0%
- ROE-235.5%+5.4%
SNGX Key Insights
Soligenix, Inc. (SNGX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.4x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 2 (bottom 2%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SNGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SNGX Price & Volume
Soligenix, Inc. (SNGX) stock price & volume — 10-year historical chart
Loading chart...
SNGX Growth Metrics
Soligenix, Inc. (SNGX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-14.25%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM54.61%
Return on Capital
10 Years-273.83%
5 Years-362.69%
3 Years-527.33%
Last Year-245.39%
SNGX Recent Earnings
Soligenix, Inc. (SNGX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 2/12 qtrs (33%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.28+6.7%
$0.30
Rev
—
—
Q2 2026
Apr 3, 2026Metric
Actual
Est
EPS
$0.32+218.5%
$0.27
Rev
—
—
Q4 2025
Nov 7, 2025Metric
Actual
Est
EPS
$0.58+7.9%
$0.63
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.82-3.8%
$0.79
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.28vs $0.30+6.7% | — |
| Q2 2026 | Apr 3, 2026 | $0.32vs $0.27+218.5% | — |
| Q4 2025 | Nov 7, 2025 | $0.58vs $0.63+7.9% | — |
| Q3 2025 | Aug 14, 2025 | $0.82vs $0.79-3.8% | — |
Based on last 12 quarters of dataView full earnings history →
SNGX Peer Comparison
Soligenix, Inc. (SNGX) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 XTLB | 279.46K | 2.54 | -0.26 | -227.72% | -25.53% | 0.03 | ||
 ADXN | 4.47M | 6.20 | -0.72 | -92.58% | -101.41% | -102.59% | 0.01 | |
 NUVB | 1.93B | 5.56 | -9.27 | 6.99% | -102.06% | -44.1% | 0.03 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 CASI | 2.33M | 0.15 | -0.06 | -15.77% | -183.93% | -301.8% | 11.96 | |
 TGTX | 8.15B | 53.22 | 19.21 | 87.32% | 65.95% | 87.36% | 0.40 | |
 CRL | 8.91B | 185.00 | -63.57 | -0.85% | -4.59% | -5.66% | 0.95 |
Compare SNGX vs Peers
Soligenix, Inc. (SNGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SNGX Income Statement
Soligenix, Inc. (SNGX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 5.43M | 5.24M | 3.22M | 1.93M | 33.35K | 250K | 0 | 0 | 0 | 0 |
Revenue Growth % | -48.01% | -3.52% | -38.64% | -39.96% | -98.27% | 649.6% | -100% | - | - | - |
Cost of Goods Sold | 4.31M | 4.6M | 3.57M | 1.82M | 728.64K | 550.82K | 742.05K | 119.37K | 0 | 2.1K |
COGS % of Revenue | 79.34% | 87.73% | 110.94% | 94.32% | 2184.76% | 220.33% | - | - | - | - |
Gross Profit | 1.12M▲ 0% | 643.73K▼ 42.6% | -351.78K▼ 154.6% | 109.58K▲ 131.2% | -695.29K▼ 734.5% | -300.82K▲ 56.7% | -742.05K▼ 146.7% | -119.37K▲ 83.9% | 0▲ 100.0% | -2.1K▲ 0% |
Gross Margin % | 20.66% | 12.28% | -10.94% | 5.68% | -2084.76% | -120.33% | - | - | - | - |
Gross Profit Growth % | -44.32% | -42.63% | -154.65% | 131.15% | -734.48% | 56.73% | -146.67% | 83.91% | 100% | - |
Operating Expenses | 8.03M | 8.43M | 10.19M | 18.7M | 12.4M | 13.94M | 6.96M | 9.32M | 11.85M | 11.7M |
OpEx % of Revenue | 147.88% | 160.79% | 316.87% | 968.44% | 37191.3% | 5575.23% | - | - | - | - |
Selling, General & Admin | 3.21M | 2.95M | 3.48M | 4.33M | 5.01M | 6.69M | 4.48M | 4.22M | 4.36M | 4.38M |
SG&A % of Revenue | 59.08% | 56.33% | 108.25% | 224.23% | 15018.25% | 2677.16% | - | - | - | - |
Research & Development | 5.51M | 6.75M | 8.12M | 14.8M | 8.19M | 7.94M | 3.31M | 5.22M | 7.49M | 7.33M |
R&D % of Revenue | 101.38% | 128.81% | 252.6% | 766.43% | 24544.54% | 3177.64% | - | - | - | - |
Other Operating Expenses | -683K | -1.28M | -1.41M | -428.91K | -790.92K | -698.91K | -839.36K | -119.37K | 0 | 0 |
Operating Income | -7.59M▲ 0% | -9.06M▼ 19.3% | -10.54M▼ 16.4% | -18.59M▼ 76.3% | -13.1M▲ 29.5% | -14.24M▼ 8.7% | -7.7M▲ 45.9% | -9.44M▼ 22.6% | -11.85M▼ 25.5% | -11.7M▲ 0% |
Operating Margin % | -139.8% | -172.85% | -327.8% | -962.77% | -39276.06% | -5695.56% | - | - | - | - |
Operating Income Growth % | -32.99% | -19.29% | -16.36% | -76.33% | 29.52% | -8.7% | 45.94% | -22.62% | -25.49% | - |
EBITDA | -7.53M | -9.01M | -10.49M | -18.52M | -13.06M | -14.21M | -7.69M | -9.43M | -11.84M | -11.7M |
EBITDA Margin % | -138.54% | -172.01% | -326.11% | -959.53% | -39173.64% | -5685.74% | - | - | - | - |
EBITDA Growth % | -33.9% | -19.79% | -16.32% | -76.65% | 29.47% | -8.8% | 45.89% | -22.65% | -25.53% | -10.07% |
D&A (Non-Cash Add-back) | 68.56K | 44.06K | 54.45K | 62.37K | 34.16K | 24.56K | 6.55K | 5.81K | 3.22K | 3.71K |
EBIT | -7.59M | -9.06M | -10.11M | -18.51M | -12.51M | -14.13M | -7.67M | -9.46M | -11.85M | -11.65M |
Net Interest Income | 29.91K | 158.57K | 148.97K | -10.88K | -904.5K | -822.61K | -49.13K | 213.97K | 270.17K | 37.71K |
Interest Income | 29.91K | 159.01K | 148.97K | 0 | 0 | 0 | 0 | 213.97K | 270.17K | 37.71K |
Interest Expense | 0 | 0 | 0 | 10.88K | 904.5K | 822.61K | 49.13K | 0 | 0 | 0 |
Other Income/Expense | 29.91K | 159.01K | 574.75K | 61.09K | -316.75K | -714.37K | -210.59K | 763.81K | 258.48K | 243.11K |
Pretax Income | -7.56M▲ 0% | -8.9M▼ 17.7% | -9.97M▼ 12.0% | -18.53M▼ 85.9% | -13.42M▲ 27.6% | -14.95M▼ 11.5% | -7.91M▲ 47.1% | -8.68M▼ 9.7% | -11.59M▼ 33.6% | -11.46M▲ 0% |
Pretax Margin % | -139.25% | -169.81% | -309.93% | -959.6% | -40225.83% | -5981.31% | - | - | - | - |
Income Tax | -417K | 0 | -610.68K | -836.89K | -864.74K | -1.15M | -1.77M | -409.11K | -506.62K | -506.62K |
Effective Tax Rate % | 5.51% | 0% | 6.13% | 4.52% | 6.45% | 7.72% | 22.35% | 4.72% | 4.37% | 4.42% |
Net Income | -7.15M▲ 0% | -8.9M▼ 24.5% | -9.36M▼ 5.1% | -17.69M▼ 89.1% | -12.55M▲ 29.0% | -13.8M▼ 9.9% | -6.14M▲ 55.5% | -8.27M▼ 34.6% | -11.08M▼ 34.0% | -10.95M▲ 0% |
Net Margin % | -131.57% | -169.81% | -290.94% | -916.25% | -37632.97% | -5519.34% | - | - | - | - |
Net Income Growth % | -120.25% | -24.53% | -5.12% | -89.07% | 29.04% | -9.94% | 55.5% | -34.62% | -34.04% | -14.25% |
Net Income (Continuing) | -7.15M | -8.9M | -9.36M | -17.69M | -12.55M | -13.8M | -6.14M | -8.27M | -11.08M | -10.95M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -278.40▲ 0% | -162.09▲ 41.8% | -115.88▲ 28.5% | -154.45▼ 33.3% | -75.06▲ 51.4% | -76.89▼ 2.4% | -12.66▲ 83.5% | -4.98▲ 60.7% | -2.14▲ 57.0% | -1.08▲ 0% |
EPS Growth % | 13.43% | 41.78% | 28.51% | -33.28% | 51.4% | -2.44% | 83.53% | 60.66% | 57.03% | 54.61% |
EPS (Basic) | -278.40 | -162.09 | -115.88 | -154.45 | -67.54 | -76.96 | -12.66 | -4.98 | -2.14 | - |
Diluted Shares Outstanding | 25.6K | 54.91K | 80.73K | 114.53K | 185.8K | 179.46K | 484.88K | 1.66M | 5.19M | 10.16M |
Basic Shares Outstanding | 25.6K | 54.91K | 80.73K | 114.53K | 185.8K | 179.29K | 484.88K | 1.66M | 5.19M | 10.16M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
SNGX Balance Sheet
Soligenix, Inc. (SNGX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 9.42M | 10.34M | 7.49M | 19.47M | 26.57M | 13.85M | 9.51M | 8.83M | 8.85M | 6.57M |
Cash & Short-Term Investments | 7.81M | 8.98M | 5.42M | 18.68M | 26.04M | 13.36M | 8.45M | 7.82M | 7.94M | 6.03M |
Cash Only | 7.81M | 8.98M | 5.42M | 18.68M | 26.04M | 13.36M | 8.45M | 7.82M | 7.94M | 6.03M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 1.34M | 1.2M | 1.46M | 564.87K | 242.72K | 219.33K | 195.15K | 0 | 0 | 0 |
Days Sales Outstanding | 90.25 | 83.69 | 166.05 | 106.8 | 2.66K | 320.22 | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 274.21K | 866.01K | 1.01M | 912.85K | 535.82K |
Total Non-Current Assets | 133.85K | 148.99K | 282.04K | 424.23K | 300.41K | 426.56K | 290.01K | 137.85K | 386.51K | 357.39K |
Property, Plant & Equipment | 37.16K | 19.63K | 161.5K | 251.54K | 128.38K | 359.47K | 241.76K | 115.08K | 354.96K | 326.94K |
Fixed Asset Turnover | 146.17x | 266.93x | 19.91x | 7.67x | 0.26x | 0.70x | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 73.95K | 46.86K | 19.7K | 23.25K | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 73.14K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 22.73K | 82.5K | 100.83K | 172.69K | 172.03K | 67.1K | 48.24K | 22.78K | 31.55K | 30.45K |
Total Assets | 9.55M▲ 0% | 10.49M▲ 9.9% | 7.78M▼ 25.9% | 19.89M▲ 155.8% | 26.87M▲ 35.1% | 14.28M▼ 46.9% | 9.8M▼ 31.4% | 8.97M▼ 8.5% | 9.24M▲ 3.0% | 6.92M▲ 0% |
Asset Turnover | 0.57x | 0.50x | 0.41x | 0.10x | 0.00x | 0.02x | - | - | - | 0.00x |
Asset Growth % | -6.99% | 9.86% | -25.89% | 155.82% | 35.08% | -46.86% | -31.39% | -8.48% | 3% | -41.44% |
Total Current Liabilities | 3.23M | 4.21M | 6.31M | 6.08M | 6.29M | 16.52M | 6.15M | 4.85M | 3.7M | 3.62M |
Accounts Payable | 1.75M | 2.13M | 2.74M | 2.13M | 2.93M | 3.87M | 1.11M | 667.9K | 1.12M | 828.66K |
Days Payables Outstanding | 148.51 | 168.78 | 279.88 | 426.92 | 1.47K | 2.56K | 546.59 | 2.04K | - | 165.32K |
Short-Term Debt | 0 | 0 | 0 | 324.98K | 0 | 9.9M | 2.25M | 1.37M | 0 | 117.23K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 298.17K | 0 | 302.94K | 336.69K | 2.42M | 336.44K | 488.13K | 2.67M |
Current Ratio | 2.92x | 2.46x | 1.19x | 3.20x | 4.22x | 0.84x | 1.55x | 1.82x | 2.39x | 1.81x |
Quick Ratio | 2.92x | 2.46x | 1.19x | 3.20x | 4.22x | 0.84x | 1.55x | 1.82x | 2.39x | 1.81x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 0 | 0 | 6.15K | 10.07M | 9.86M | 233.67K | 1.12M | 0 | 244.12K | 213.43K |
Long-Term Debt | 0 | 0 | 0 | 9.95M | 9.86M | 0 | 1.01M | 0 | 0 | 213.43K |
Capital Lease Obligations | 0 | 0 | 6.15K | 116.3K | 0 | 233.63K | 111.86K | 0 | 244.12K | 820.63K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 43 | 0 | 0 | 0 | 0 |
Total Liabilities | 3.23M | 4.21M | 6.32M | 16.15M | 16.15M | 16.75M | 7.27M | 4.85M | 3.94M | 3.83M |
Total Debt | 0 | 0 | 127.22K | 10.51M | 9.96M | 10.24M | 3.49M | 1.48M | 358.14K | 330.66K |
Net Debt | -7.81M | -8.98M | -5.29M | -8.17M | -16.08M | -3.12M | -4.95M | -6.33M | -7.58M | -5.7M |
Debt / Equity | - | - | 0.09x | 2.81x | 0.93x | - | 1.39x | 0.36x | 0.07x | 0.11x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.49x |
Interest Coverage | - | - | - | -1701.39x | -13.83x | -17.18x | -156.20x | - | - | - |
Total Equity | 6.32M▲ 0% | 6.28M▼ 0.6% | 1.46M▼ 76.8% | 3.74M▲ 156.8% | 10.72M▲ 186.6% | -2.47M▼ 123.0% | 2.52M▲ 202.1% | 4.12M▲ 63.3% | 5.29M▲ 28.5% | 3.09M▲ 0% |
Equity Growth % | -14.57% | -0.63% | -76.8% | 156.79% | 186.56% | -123.04% | 202.09% | 63.26% | 28.51% | -5.15% |
Book Value per Share | 246.85 | 114.37 | 18.05 | 32.67 | 57.71 | -13.77 | 5.20 | 2.48 | 1.02 | 0.30 |
Total Shareholders' Equity | 6.32M | 6.28M | 1.46M | 3.74M | 10.72M | -2.47M | 2.52M | 4.12M | 5.29M | 3.09M |
Common Stock | 8.73K | 17.68K | 21.75K | 30.64K | 2.86K | 2.91K | 10.38K | 2.51K | 10.09K | 10.52K |
Retained Earnings | -157.27M | -166.17M | -175.53M | -193.21M | -205.77M | -219.56M | -225.7M | -233.97M | -245.05M | -247.88M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -3.67K | -45.01K | -24.34K | 41.94K | 24.75K | 22.24K | 45.79K | 45.79K | 45.79K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SNGX Cash Flow Statement
Soligenix, Inc. (SNGX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -6.51M | -7.24M | -7.51M | -11.45M | -11.74M | -12.65M | -8.6M | -8.4M | -10.27M | -10.78M |
Operating CF Margin % | -119.86% | -138.23% | -233.53% | -593.33% | -35200.2% | -5059.61% | - | - | - | - |
Operating CF Growth % | -30.67% | -11.28% | -3.66% | -52.53% | -2.49% | -7.75% | 31.98% | 2.33% | -22.17% | -94.32% |
Net Income | -7.15M | -8.9M | -9.36M | -17.69M | -12.55M | -13.8M | -6.14M | -8.27M | -11.08M | -10.95M |
Depreciation & Amortization | 68.56K | 44.06K | 54.45K | 62.37K | 34.16K | 24.56K | 6.55K | 5.81K | 3.22K | 3.71K |
Stock-Based Compensation | 489.79K | 380.89K | 376.34K | 409.93K | 361.56K | 333.39K | 370.18K | 329.81K | 587.58K | 523.98K |
Deferred Taxes | 0 | 0 | -3.84K | 0 | -421.58K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 5.92K | 1.48K | 282.35K | 5.25M | 185.72K | 366.25K | 597.4K | -124.26K | 191.2K | 263.61K |
Working Capital Changes | 72.24K | 1.23M | 1.14M | 509.31K | 651.5K | 425.11K | -3.44M | -348.41K | 31.82K | -924.95K |
Change in Receivables | 280.53K | -275.46K | 182.88K | 815.06K | 64.89K | 23.76K | 33.89K | 219.9K | 0 | 0 |
Change in Inventory | 0 | 0 | -1.97M | 1.16M | -1.13M | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 382.71K | 1.02M | 1.97M | -1.16M | 1.13M | 396.65K | -2.69M | -492.61K | -16.5K | -670.98K |
Cash from Investing | -26.35K | -925 | -24.71K | -7.15K | -11.79K | -13.07K | 0 | 0 | -5.88K | -5.88K |
Capital Expenditures | -26.35K | -1.93K | -30.21K | -7.15K | -11.79K | -13.07K | 0 | 0 | -5.88K | 0 |
CapEx % of Revenue | 0.49% | 0.04% | 0.94% | 0.37% | 35.35% | 5.23% | - | - | - | - |
Acquisitions | 0 | 1K | 5.5K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 1K | 5.5K | 0 | 0 | 0 | 0 | 0 | 0 | -5.88K |
Cash from Financing | 5.57M | 8.42M | 4.01M | 24.68M | 19.06M | 76.82K | 3.66M | 7.76M | 10.39M | 9.52M |
Debt Issued (Net) | 0 | 0 | -6.8K | 9.99M | -6.15K | 0 | -7M | -1.37M | -1.37M | 1.37M |
Equity Issued (Net) | 6.25M | 8.68M | 4.14M | 14.62M | 19.71M | 79.35K | 11.59M | 5.81M | 12.47M | 10.08M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -672.36K | -251.89K | -130.2K | 68.17K | -641.5K | -2.53K | -923.77K | 3.32M | -708.24K | -1.94M |
Net Change in Cash | -963.08K▲ 0% | 1.17M▲ 221.9% | -3.56M▼ 403.4% | 13.26M▲ 472.0% | 7.37M▼ 44.4% | -12.68M▼ 272.2% | -4.91M▲ 61.3% | -626.64K▲ 87.2% | 116.64K▲ 118.6% | -1.3M▲ 0% |
Free Cash Flow | -6.54M▲ 0% | -7.25M▼ 10.9% | -7.54M▼ 4.0% | -11.46M▼ 52.0% | -11.75M▼ 2.5% | -12.66M▼ 7.7% | -8.6M▲ 32.0% | -8.4M▲ 2.3% | -10.27M▼ 22.2% | -10.78M▲ 0% |
FCF Margin % | -120.34% | -138.27% | -234.47% | -593.7% | -35235.55% | -5064.84% | - | - | - | - |
FCF Growth % | -31.01% | -10.86% | -4.05% | -52.01% | -2.53% | -7.75% | 32.05% | 2.33% | -22.17% | -20.98% |
FCF per Share | -255.34 | -131.97 | -93.39 | -100.08 | -63.25 | -70.56 | -17.74 | -5.06 | -1.98 | -1.06 |
FCF Conversion (FCF/Net Income) | 0.91x | 0.81x | 0.80x | 0.65x | 0.94x | 0.92x | 1.40x | 1.02x | 0.93x | 0.98x |
Interest Paid | 0 | 0 | 0 | 34.41K | 668.72K | 857.41K | 552.06K | 227.74K | 35.04K | 0 |
Taxes Paid | -5.08K | 2.58K | 11.13K | 4.02K | 7.73K | 16.04K | 20.73K | 42.16K | 122.16K | 65.99K |
SNGX Key Ratios
Soligenix, Inc. (SNGX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -104.21% | -141.27% | -241.83% | -680.46% | -173.54% | -334.43% | -23803.12% | -248.97% | -235.5% | -246.04% |
Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | 341.07% |
Gross Margin | 20.66% | 12.28% | -10.94% | 5.68% | -2084.76% | -120.33% | - | - | - | - |
Net Margin | -131.57% | -169.81% | -290.94% | -916.25% | -37632.97% | -5519.34% | - | - | - | - |
Debt / Equity | - | - | 0.09x | 2.81x | 0.93x | - | 1.39x | 0.36x | 0.07x | 0.11x |
Interest Coverage | - | - | - | -1701.39x | -13.83x | -17.18x | -156.20x | - | - | - |
FCF Conversion | 0.91x | 0.81x | 0.80x | 0.65x | 0.94x | 0.92x | 1.40x | 1.02x | 0.93x | 0.98x |
Revenue Growth | -48.01% | -3.52% | -38.64% | -39.96% | -98.27% | 649.6% | -100% | - | - | - |
Related:SNGX Dividend History·SNGX Revenue History·SNGX Price History·SNGX P/E History·SNGX Financial Ratios·SNGX Institutional Holders
SNGX SEC Filings & Documents
Soligenix, Inc. (SNGX) SEC filings — annual & quarterly reports (10-K, 10-Q)
SNGX Frequently Asked Questions
Soligenix, Inc. (SNGX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Soligenix, Inc. (SNGX) grew revenue by 0.0% over the past year. Growth has been modest.
Soligenix, Inc. (SNGX) reported a net loss of $11.0M for fiscal year 2025.
Dividend & Returns
Soligenix, Inc. (SNGX) has a return on equity (ROE) of -235.5%. Negative ROE indicates the company is unprofitable.
Soligenix, Inc. (SNGX) had negative free cash flow of $10.8M in fiscal year 2025, likely due to heavy capital investments.